Recent Financing
Recent Raise
Arnatar develops RNA therapeutics with ACT‑UP1 and DARGER (siRNA plus upregulating ASOs); lead ART4 upregulates JAG1 with monthly subcutaneous dosing and targets cardiometabolic, liver, CNS, kidney diseases.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
